MINNEAPOLIS, July 1 /PRNewswire/ -- Dermatrends, Inc., a drug delivery company, announced today that it has received a U.S. patent that covers the method of using bases to enhance the permeation of amine drugs across the skin. The patent is the eleventh granted to Dermatrends, all related to its breakthrough technology in the field of transdermal patch drug delivery. It covers the very wide drug category of amine drugs which includes a variety of compounds used to treat conditions ranging from Alzheimer's disease, to enlarged prostate, to acid reflux disease. To date, prescription drugs used in the treatment of these diseases have been available primarily in oral delivery format.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040701/CGTH053LOGO )
Dermatrends' new U.S. patent number 6,719,997 covers the use of hydroxide releasing agents with amine drugs. In its application, Dermatrends demonstrated that its base hydroxide-releasing agent was able to increase flux rates, or permeation. The newly issued patent adds to an intellectual property portfolio that includes a broad method patent for its enhancer system as well as numerous patents for its technology applied to large categories of drugs. These include peptides and non-steroidal anti-inflammatory drugs (NSAIDs). The company has also been issued patents for its technology applied to specific drug compounds.
Amine drugs are a very broad category of therapeutic drugs with approved compounds numbering literally in the thousands. Widely prescribed drugs in this category include donepezil and galantamine HBr, both used to treat Alzheimer's disease, and also the compounds tamsulosin, finasteride and dutasteride, all of which are used in the treatment of benign prostatic hyperplasia (BPH), commonly known as enlargement of the prostate. Another class of amine drugs includes proton pump inhibitors such as omeprazole, rabeprazole and lansoprazole, which are used to treat a form of acid reflux disease. Amine drugs also include compounds commonly used for pain relief, antidepressants, and amphetamines such as Ritalin(R), one of the drugs used to treat attention deficit hyperactive disorder (ADHD).
Dermatrends is currently working with pharmaceutical partners to bring its technology to consumers. Depending on the condition being treated, there are a number of potential consumer benefits to having the choice of a patch delivery alternative to an oral prescription. These benefits include improved patient compliance and minimization or elimination of side effects associated with oral delivery.
Dermatrends Chairman and Chief Executive Officer Ted Schwarzrock, said, "Dermatrends continues to break through existing barriers that have limited transdermal patch delivery to a very small number of compounds. The patent we are announcing today is another example of our ability to offer the pharmaceutical industry a new form of drug delivery technology that can open up a huge class of pharmacological compounds for transdermal delivery."
Dermatrends, Inc. is a privately held medical research and development company based in Minneapolis, Minn. with scientific laboratories in San Diego, Calif. The company is dedicated to the development of proprietary transdermal and other drug delivery technologies, and it has demonstrated an enabling platform technology that allows a broad variety of ethical and over-the- counter drugs to permeate the skin and mucosal surface and enter the bloodstream at therapeutic levels in excess of anything currently commercially available. The company is currently actively developing its partnerships and other relationships in the global pharmaceutical industry to commercially introduce its technology. Additional information is available on the company's website at http://www.dermatrends.com/ . For additional information, please email us at firstname.lastname@example.org or call 612.843.2142.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, email@example.comDermatrends, Inc.